Cancer

FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the…

1 year ago

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update…

1 year ago

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…

1 year ago

Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

1 year ago

Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX:…

1 year ago

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across…

1 year ago

50% Imaging Error Rate in Clinical Trials Discussed by Expert Panelists from 5 NCI-Designated Cancer Centers

Data points to a broader industry-wide imaging accuracy crisisCHICAGO, IL / ACCESSWIRE / July 23, 2024 / Yunu, a provider…

1 year ago

David Rubenstein Joins Moderna’s Board of Directors

Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen BerensonCo-founder…

1 year ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics…

1 year ago

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals…

1 year ago